Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Jan;227(1):120-5.
doi: 10.1097/00000658-199801000-00017.

Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients

G E O'Keefe  1 , L M Gentilello, R V Maier
Affiliations
Comparative Study

Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients

G E O'Keefe et al. Ann Surg. 1998 Jan.

Abstract

Objective: To determine the impact of histamine2 (H2)-receptor antagonist use on the occurrence of infectious complications in severely injured patients.

Summary background data: Some previous studies suggest an increased risk of nosocomial pneumonia associated with the use of H2-receptor blockade in critically ill patients, but other investigations suggest an immune-enhancing effect of H2-receptor antagonists. The purpose of this study was to determine whether H2-receptor antagonist use affects the overall incidence of infectious complications.

Methods: Patients enrolled in a randomized trial comparing ranitidine with sucralfate for gastritis prophylaxis were examined for all infectious complications during their hospitalization. Data on the occurrence of pneumonia were prospectively collected, and other infectious complications were retrospectively obtained from the medical record. The relative risk of infectious complications associated with ranitidine use and total infectious complications were analyzed.

Results: Of 98 patients included, the charts of 96 were available for review. Sucralfate was given to 47, and 49 received ranitidine. Demographic factors were similar between the groups. Ranitidine use was associated with a 1.5-fold increased risk of developing any infectious complication (37 of 47 vs. 26 of 47; 95% confidence interval, 1.04 to 2.28). Infectious complications totaled 128 in the ranitidine-treated group and 50 in the sucralfate-treated group (p = 0.0014). These differences remained after excluding catheter-related infections (p = 0.0042) and secondary bacteremia (p = 0.0046).

Conclusions: Ranitidine use in severely injured patients is associated with a statistically significant increase in overall infectious complications when compared with sucralfate. These results indicate that ranitidine should be avoided where possible in the prophylaxis of stress gastritis.

PubMed Disclaimer

References

    1. Ann Intern Med. 1987 Apr;106(4):562-7 - PubMed
    1. JAMA. 1996 Jan 24-31;275(4):308-14 - PubMed
    1. Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S585-93 - PubMed
    1. Am J Surg. 1988 Dec;156(6):437-40 - PubMed
    1. Chest. 1991 Jul;100(1):7-13 - PubMed

Publication types